Vyne Therapeutics Inc. (VYNE)

Market Closed

16 Oct, 08:00 PM

NASDAQ (CM)

18. 31

-0.59

-3.1217%

19.07M Market Cap

- P/E Ratio

- Div Yield

60,721 Volume

-1 Eps

$ 18.9

Previous Close

Investors:

Add Transaction

Day Range

18.05 20.1

Year Range

0.32 46.95

Want to track VYNE and more in your Portfolio? 🎯

Get Started For Free

VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript

Seekingalpha | 10 months ago

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.29 per share a year ago.

Zacks | 11 months ago

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.22 per share a year ago.

Zacks | 1 year ago

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $1.85 per share a year ago.

Zacks | 1 year ago

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $3.08 per share a year ago.

Zacks | 2 years ago

Blog Affiliate Program Dividend Tracker About Terms Privacy Help Contact Us